Search

Your search keyword '"Razavi, H."' showing total 790 results
Start Over Author "Razavi, H."
790 results on '"Razavi, H."'

2. Adjusted estimate of the prevalence of hepatitis delta virus in 25 countries and territories

Author

Razavi-Shearer, D., Child, H., Razavi-Shearer, K., Voeller, A., Razavi, H., Buti, M., Tacke, F., Terrault, N., Zeuzem, S., Abbas, Z., Aghemo, A., Akarca, U.S., Al Masri, N., Alalwan, A., Blomé, M. Alanko, Jerkeman, A., Aleman, S., Kamal, H., Alghamdi, A., Alghamdi, M., Alghamdi, S., Al-Hamoudi, W., Ali, E., Aljumah, A., Altraif, I., Amarsanaa, J., Asselah, T., Baatarkhuu, O., Babameto, A., Ben-Ari, Z., Berg, T., Biondi, M., Braga, W., Brandão-Mello, C., Brown, R., Brunetto, M., Cabezas, J., Cardoso, M., Martins, A., Chan, H.L.Y., Cheinquer, H., Chen, C.-J., Yang, H.-I., Chen, P.-J., Chien, C.-H., Chuang, W.-L., Garza, L. Cisneros, Coco, B., Coffin, C., Coppola, N., Cornberg, M., Craxi, A., Crespo, J., Cuko, L., De Ledinghen, V., Duberg, A.-S., Etzion, O., Ferraz, M.L., Ferreira, P., Forns, X., Foster, G., Fung, J., Gaeta, G., García-Samaniego, J., Genov, J., Gheorghe, L., Gholam, P., Gish, R., Glenn, J., Hamid, S., Hercun, J., Hsu, Y.-C., Hu, C.-C., Huang, J.-F., Idilman, R., Jafri, W., Janjua, N., Jelev, D., Jia, J., Kåberg, M., Kaita, K., Kao, J.-H., Khan, A., Kim, D.Y., Kondili, L., Lagging, M., Lampertico, P., Lázaro, P., Lazarus, J.V., Lee, M.-H., Lim, Y.-S., Lobato, C., Macedo, G., Marinho, R., Marotta, P., Mendes-Correa, M.C., Méndez-Sánchez, N., Navas, M.-C., Ning, Q., Örmeci, N., Orrego, M., Osiowy, C., Pan, C., Pessoa, M., Piracha, Z., Pop, C., Qureshi, H., Raimondo, G., Ramji, A., Ribeiro, S., Ríos-Hincapié, C., Rodríguez, M., Rosenberg, W., Roulot, D., Ryder, S., Saeed, U., Safadi, R., Shouval, D., Sanai, F., Sanchez-Avila, J.F., Santantonio, T., Sarrazin, C., Seto, W.-K., Simonova, M., Tanaka, J., Tergast, T., Tsendsuren, O., Valente, C., Villalobos-Salcedo, J.M., Waheed, Y., Wong, G., Wong, V., Yip, T., Wu, J.-C., Yu, M.-L., Yuen, M.-F., Yurdaydin, C., and Zuckerman, E.

Published
2024
Full Text
View/download PDF

3. Subthreshold Nanosecond Laser in Age-Related Macular Degeneration: Observational Extension Study of the LEAD Clinical Trial

Author

Al-Qureshi, S., Busija, L., I, Louis, D., Harper, C., Wickremasinghe, S., Van Wijngaarden, P., Lim, L., Durkin, S., Runciman, J., Gihotra, J., Muecke, J., Haywood, K., Brko, C., Paley, J., Smith, M., Luscombe, C., Vincent, R., Lee, D., Guymer, R.H., Luu, C., Wu, Z., Hodgson, L.A.B., Brassington, K., Caruso, E., McGuinness, M., Tindill, N., Aung, K.Z., Baglin, E., Sharangan, P., Harper, C.A., Sandhu, S., Nguyen, T., Cohn, A., Qatarneh, D., Robman, L., Makeyeva, G., Tan, R., Taori, S., Creese, K., Chen, M., Ong, D., No, S., Kandasamy, R., Lim, S.W., Okada, M., Cugley, D., O'Day, R., Keller, P., Lee, K., Alessandrello, E., Alessi-Calandro, J., Kolic, M., Wu, T., Griffin, S., Lek, J.J., Heriot, W., Fagan, X., McIntosh, R., Lowe, C., Boyle, J., Shanahan, O., Chen, F., McAllister, I., Isaacs, T., Shaw, A., Balarantnasingam, C., Chen, Y., Cunningham, W., Viljoen, R., Kennelly, K., Blum, R., Arunachalam, S., Razavi, H., Adams, M., Brown, H., Bryant, J., Cowles, R., Radtke, S., Barry, C., Wong, E., Shilton, F., Soloshenko, A., Jason, A., Lin, A., McSweeney, A., King, A., Shalan, B., Xie, D., Vu, H., Tang, I., Mather, K., Cuypers, M., Cheng, M., McKeone, R., Busby, T., Matthews, R., Lingham, G., Arnold, J., Luckie, A., Chan, D., Chang, J., Tan, T., Koh, L., Cass, H., Fitzsimons, R., Forsyth, T., Nguyen, A., Ghebrial, V., Ayson, H., Graham, A., Firibaldi, M., Chakravarthy, U., Kelly, L., Gillvray, K., Williams, M., Casalino, G., Mangoris, G., Das, R., Peto, T., Toth, L., Quinn, M., Denham, R., Lavery, N.J., Sterrett, G., Silvestri, V., Young, G., Graham, K., Keenan, J., Doyle, L., Douglas, T., Burns, D., Wright, P., Scullion, L., Guymer, Robyn H., Chen, Fred K., Hodgson, Lauren A.B., Caruso, Emily, Harper, Colin A., Wickremashinghe, Sanjeewa S., Cohn, Amy C., Sivarajah, Pyrawy, Tindill, Nicole, Luu, Chi D., and Wu, Zhichao

Published
2021
Full Text
View/download PDF

4. The adjusted prevalence of hepatitis delta virus (HDV) in 25 countries and territories

Author

Razavi-Shearer, D., primary, Child, H., additional, Razavi-Shearer, K., additional, Voeller, A., additional, Razavi, H., additional, Buti, M., additional, Tacke, F., additional, Terrault, N., additional, Zeuzem, S., additional, Abbas, Z., additional, Aghemo, A., additional, Akarca, U.S., additional, Al Masri, N., additional, Alalwan, A., additional, Blomé, M Alanko, additional, Jerkeman, A., additional, Aleman, S., additional, Kamal, H., additional, Alghamdi, A., additional, Alghamdi, M., additional, Alghamdi, S., additional, Al-Hamoudi, W., additional, Ali, E., additional, Aljumah, A., additional, Altraif, I., additional, Amarsanaa, J., additional, Asselah, T., additional, Baatarkhuu, O., additional, Babameto, A., additional, Ben-Ari, Z., additional, Berg, T., additional, Biondi, M., additional, Braga, W., additional, Brandão-Mello, C., additional, Brown, R., additional, Brunetto, M., additional, Cabezas, J., additional, Cardoso, M., additional, Martins, A., additional, Chan, H.L.Y., additional, Cheinquer, H., additional, Chen, C.-J., additional, Yang, H.-I., additional, Chen, P.-J., additional, Chien, C.-H., additional, Chuang, W.-L., additional, Garza, L Cisneros, additional, Coco, B., additional, Coffin, C., additional, Coppola, N., additional, Cornberg, M., additional, Craxi, A., additional, Crespo, J., additional, Cuko, L., additional, De Ledinghen, V., additional, Duberg, A.-S., additional, Etzion, O., additional, Ferraz, M.L., additional, Ferreira, P., additional, Forns, X., additional, Foster, G., additional, Fung, J., additional, Gaeta, G., additional, García-Samaniego, J., additional, Genov, J., additional, Gheorghe, L., additional, Gholam, P., additional, Gish, R., additional, Glenn, J., additional, Hamid, S., additional, Hercun, J., additional, Hsu, Y.-C., additional, Hu, C.-C., additional, Huang, J.-F., additional, Idilman, R., additional, Jafri, W., additional, Janjua, N., additional, Jelev, D., additional, Jia, J., additional, Kåberg, M., additional, Kaita, K., additional, Kao, J.-H., additional, Khan, A., additional, Kim, D.Y., additional, Kondili, L., additional, Lagging, M., additional, Lampertico, P., additional, Lázaro, P., additional, Lazarus, J.V., additional, Lee, M.-H., additional, Lim, Y.-S., additional, Lobato, C., additional, Macedo, G., additional, Marinho, R., additional, Marotta, P., additional, Mendes-Correa, M.C., additional, Méndez-Sánchez, N., additional, Navas, M.-C., additional, Ning, Q., additional, Örmeci, N., additional, Orrego, M., additional, Osiowy, C., additional, Pan, C., additional, Pessoa, M., additional, Piracha, Z., additional, Pop, C., additional, Qureshi, H., additional, Raimondo, G., additional, Ramji, A., additional, Ribeiro, S., additional, Ríos-Hincapié, C., additional, Rodríguez, M., additional, Rosenberg, W., additional, Roulot, D., additional, Ryder, S., additional, Saeed, U., additional, Safadi, R., additional, Shouval, D., additional, Sanai, F., additional, Sanchez-Avila, J.F., additional, Santantonio, T., additional, Sarrazin, C., additional, Seto, W.-K., additional, Simonova, M., additional, Tanaka, J., additional, Tergast, T., additional, Tsendsuren, O., additional, Valente, C., additional, Villalobos-Salcedo, J.M., additional, Waheed, Y., additional, Wong, G., additional, Wong, V., additional, Yip, T., additional, Wu, J.-C., additional, Yu, M.-L., additional, Yuen, M.-F., additional, Yurdaydin, C., additional, and Zuckerman, E., additional

Published
2023
Full Text
View/download PDF

8. The new paradigm of hepatitis C therapy: integration of oral therapies into best practices

Author

Afdhal, NH, Zeuzem, S, Schooley, RT, Thomas, DL, Ward, JW, Litwin, AH, Razavi, H, Castera, L, Poynard, T, Muir, A, Mehta, SH, Dee, L, Graham, C, Church, DR, Talal, AH, Sulkowski, MS, Jacobson, IM, and Participants, for the New Paradigm of HCV Therapy Meeting

Subjects
Emerging Infectious Diseases, Liver Disease, Hepatitis, Health Services, Prevention, Orphan Drug, Digestive Diseases, Infectious Diseases, Rare Diseases, Clinical Research, Hepatitis - C, Chronic Liver Disease and Cirrhosis, Infection, Good Health and Well Being, Administration, Oral, Antiviral Agents, Centers for Disease Control and Prevention, U.S., Hepatitis C, Chronic, Humans, Liver, Mass Screening, Practice Guidelines as Topic, United States, diagnosis, directly acting antiviral agents, health services, hepatitis C, pharmacoeconomics, New Paradigm of HCV Therapy Meeting Participants, Microbiology, Clinical Sciences, Medical Microbiology, Gastroenterology & Hepatology
Abstract

Emerging data indicate that all-oral antiviral treatments for chronic hepatitis C virus (HCV) will become a reality in the near future. In replacing interferon-based therapies, all-oral regimens are expected to be more tolerable, more effective, shorter in duration and simpler to administer. Coinciding with new treatment options are novel methodologies for disease screening and staging, which create the possibility of more timely care and treatment. Assessments of histologic damage typically are performed using liver biopsy, yet noninvasive assessments of histologic damage have become the norm in some European countries and are becoming more widespread in the United States. Also in place are new Centers for Disease Control and Prevention (CDC) initiatives to simplify testing, improve provider and patient awareness and expand recommendations for HCV screening beyond risk-based strategies. Issued in 2012, the CDC recommendations aim to increase HCV testing among those with the greatest HCV burden in the United States by recommending one-time testing for all persons born during 1945-1965. In 2013, the United States Preventive Services Task Force adopted similar recommendations for risk-based and birth-cohort-based testing. Taken together, the developments in screening, diagnosis and treatment will likely increase demand for therapy and stimulate a shift in delivery of care related to chronic HCV, with increased involvement of primary care and infectious disease specialists. Yet even in this new era of therapy, barriers to curing patients of HCV will exist. Overcoming such barriers will require novel, integrative strategies and investment of resources at local, regional and national levels.

Published
2013

9. Effect of Pr doping on the superconductivity and interlayer coupling of Bi2Sr2-xPrxCa1Cu2Oy system

Author

Razavi, H. Salamati P. Kameli F. S.

Subjects
Condensed Matter - Superconductivity, Condensed Matter - Strongly Correlated Electrons
Abstract

The effect of Pr substitution on the superconductivity and interlayer coupling of Bi2212 system is investigated. Magnetic and transport measurements were performed for purposes of characterization. The superconducting transition temperature Tc first increased and then decreased till it became zero at x=0.6. The effective superconducting volume also decreases due to Pr substitution. From the fluctuation conductivity analyses it is found that the interlayer coupling constant J decreases monotonically with increase of the Pr content. This result shows that the Pr doping weakens the CuO2 interlayer coupling of Bi2212 system due to the loss of local superconductivity in the CuO2 layers., Comment: 14pages, 5figures, 1 table

Published
2002

10. Global reporting of progress towards elimination of hepatitis B and hepatitis C

Author

Cui, F, Blach, S, Manzengo Mingiedi, C, Gonzalez, MA, Sabry Alaama, A, Mozalevskis, A, Séguy, N, Rewari, BB, Chan, P-L, Le, L-V, Doherty, M, Luhmann, N, Easterbrook, P, Dirac, M, De Martel, C, Nayagam, S, Hallett, TB, Vickerman, P, Razavi, H, Lesi, O, and Low-Beer, D

Subjects
Hepatology, Gastroenterology
Abstract

BACKGROUND: The 69th World Health Assembly endorsed the global health sector strategy on viral hepatitis to eliminate viral hepatitis as a public health threat by 2030. Achieving and measuring the 2030 targets requires a substantial increase in the capacity to test and treat viral hepatitis infections and a mechanism to monitor the progress of hepatitis elimination. This study aimed to identify the gaps in data availability or quality and create a new mechanism to monitor the progress of hepatitis elimination. METHODS: In 2020, using a questionnaire, we collected empirical, systematic, modelled, or surveyed data-reported by WHO country and WHO regional offices-on indicators of progress towards elimination of viral hepatitis, including burden of infection, incidence, mortality, and the cascade of care, and validated these data. FINDINGS: WHO received officially validated country-provided data from 130 countries or territories, and used partner-provided data for 70 countries or territories. We estimated that in 2019, globally, 295·9 million (3·8%) people were living with chronic hepatitis B virus (HBV) infection and 57·8 million (0·8%) people were living with chronic hepatitis C virus (HCV) infection. Globally, there were more than 3·0 million new infections with HBV and HCV and more than 1·1 million deaths due to the viruses in 2019. In 2019, 30·4 million (95% CI 24·3-38·0) individuals living with hepatitis B knew their infection status and 6·6 million (5·3-8·3) people diagnosed with hepatitis B received treatment. Among people with HCV infection, 15·2 million (95% CI 12·1-19·0) had been diagnosed between 2015 and 2019, and 9·4 million (7·5-11·7) people diagnosed with hepatitis C infection were treated with direct-acting antiviral drugs between 2015 and 2019. INTERPRETATION: There has been notable global progress towards hepatitis elimination. In 2019, 30·4 million (10·3%) people living with hepatitis B knew their infection status, which was slightly higher than in 2015 (22·0 million; 9·0%), and 6·6 million (22·7%) of those diagnosed with hepatitis B received treatment, compared with 1·7 million (8·0%) in 2015. Mortality from hepatitis C has declined since 2019, driven by an increase in HCV treatment ten times that of the strategy baseline. However, an estimated 89·7% of HBV infections and 78·6% of HCV infections remain undiagnosed. A new global strategy for 2022-30, based on these new estimates, should be implemented urgently to scale up the screening and treatment of viral hepatitis. FUNDING: World Health Organization.

Published
2023
Full Text
View/download PDF

11. Development of Computer-Based Workstations for the Operation of Engineering Laboratories. Final Report.

Author

Mohanty, G. P., Kim, R. H., Peindl, R. D., Razavi, H. M., and Gretes, J. A.

Abstract

Laboratory instruction in engineering disciplines in recent years has been adversely affected by a variety of structural problems making it increasingly difficult to provide students with adequate hands-on lab experience on par with the ever expanding requirements of the technical job market. As a possible approach to deal with some of the underlying issues, this project was concerned with the development of computer integrated laboratory facilities or "laboratory workstations" with capabilities for conducting experiments directly from computer terminals. The objective was to streamline the laboratory delivery process, in addition to improving the effectiveness of hardware utilization and enhancing the overall laboratory experience of the students. The computerized system incorporates data, control signal, and video links with the laboratory facilities, and permits operational control over the hardware functions along with data acquisition and analysis, allowing students to carry out the experimental steps as well as analyze and produce hard copies of their results in different formats from the terminal. Further, through interlinkage with a distributed system of computers via local area networking, it is possible for a single lab facility to serve the experimental needs of multiple users on a quasi-time sharing basis. Includes 27-page "Report of Learner Tryout and Pilot Test Results" (John A. Gretes) summarizing student feedback from the pilot try-outs in the junior lab courses. (SWC)

Published
1994

15. Peptide based polyclonal antibody production against bovine rotavirus non structure protein4 (NSP4)

Author

Goodarzi1, Z, Soleimanjahi, H, Saberfar, E, Teimoori, A, and Razavi, H

Subjects
Rotavirus, NSP4, protein, peptide, polyclonal antibody, Veterinary medicine, SF600-1100
Abstract

The rotavirus nonstructural protein 4 (NSP4), is a multi functional protein that play key role in both viral morphogenesis and cytopathic effect associated with cell death. However, the complete biological effect of NSP4 remains to be clarified. Since to obtain further knowledge about this protein there is a need for recognizing antibody and there is no commercial antibody against this protein, this study was designed to produce polyclonal antibodies against a synthetic immunogenic peptide of RF rotavirus NSP4 protein in order to be used as diagnostic and research tool. In the present study a peptide sequences corresponding to NSP4 114-135 conjugated to Bovine Serum Albumin (BSA) by glutaraldehyde through a single-step coupling protocol. The conjugated peptides were extensively dialyzed and injected to New Zealand white rabbits. The NSP4 114-135 peptide-specific antiserum was confirmed by both IF and Western blot analysis.The result indicated successful production of polyclonal antibody raised against native NSP4 protein. In conclusion, since NSP4 is a toxic protein for the cells, it is impracticable to express full length of NSP4 protein in expression systems. Therefore, the introducing immunogenic peptide in appropriate animal may be the best approach to produce its specific antibody.

Published
2015

16. Hepatitis C: The beginning of the end—key elements for successful European and national strategies to eliminate HCV in Europe

Author

Papatheodoridis, G. V., Hatzakis, A., Cholongitas, E., Baptista‐Leite, R., Baskozos, I., Chhatwal, J., Colombo, M., Cortez‐Pinto, H., Craxi, A., Goldberg, D., Gore, C., Kautz, A., Lazarus, J. V., Mendão, L., Peck‐Radosavljevic, M., Razavi, H., Schatz, E., Tözün, N., van Damme, P., Wedemeyer, H., Yazdanpanah, Y., Zuure, F., and Manns, M. P.

Published
2018
Full Text
View/download PDF

17. Strategies to manage hepatitis C virus infection disease burden—Volume 4

Author

Chen, D. S., Hamoudi, W., Mustapha, B., Layden, J., Nersesov, A., Reic, T., Garcia, V., Rios, C., Mateva, L., Njoya, O., Al‐Busafi, S. A., Abdelmageed, M. K., Abdulla, M., Adda, D., Akin, O., Al Baqali, A., Al Dweik, N., Al Ejji, K., Al ghazzawi, I., Al Kaabi, S., Al Naamani, K., Al Qamish, J., Al Sadadi, M., Al Salman, J., AlBadri, M., Al‐Romaihi, H. E., Ampofo, W., Antonov, K., Anyaike, C., Arome, F., Bane, A., Blach, S., Borodo, M. M., Brandon, S. M., Bright, B., Butt, M. T., Cardenas, I., Chan, H. L. Y., Chen, C. J., Chen, P. J., Chien, R. N., Chuang, W. L., Cuellar, D., Derbala, M., Elbardiny, A. A., Estes, C., Farag, E., Fung, J., Gamkrelidze, I., Genov, J., Ghandour, Z., Ghuloom, M., Gomez, B., Gunter, J., Habeeb, J., Hajelssedig, O., Himatt, S. M., Hrstic, I., Hu, C. C., Huang, C. F., Hui, Y. T., Jahis, R., Jelev, D., John, A. K., Kaliaskarova, K. S., Kamel, Y., Kao, J. H., Khamis, J., Khattabi, H., Khoudri, I., Konysbekova, A., Kotzev, I., Lai, M. S., Lao, W. C., Lee, M. H., Lesi, O., Li, M., Lo, A., Loo, C. K., Lukšić, B., Maaroufi, A., Malu, A. O., Mitova, R., Mohamed, R., Morović, M., Murphy, K., Nde, H., Ngige, E., Njouom, R., Nonković, D., Obekpa, S., Oguche, S., Okolo, E. E., Omede, O., Omuemu, C., Ondoa, P., Opare‐Sem, O., Owusu‐Ofori, S., Phillips, R. O., Prokopenko, Y. N., Razavi, H., Razavi‐Shearer, D., Razavi‐Shearer, K., Redae, B., Rinke de Wit, T., Robbins, S., Roberts, L. R., Sanad, S. J., Sharma, M., Simonova, M., Su, T. H., Sultan, K., Tan, S. S., Tchernev, K., Tsang, O. T. Y., Tsang, S., Tzeuton, C., Ugoeze, S., Uzochukwu, B., Vi, R., Vince, A., Wani, H. U., Wong, V. W. S., Workneh, A., Yacoub, R., Yesmembetov, K. I., Youbi, M., Yuen, M. F., and Schmelzer, J. D.

Published
2017
Full Text
View/download PDF

18. The present and future disease burden of hepatitis C virus infections with todayʼs treatment paradigm: Volume 4

Author

Chan, H. L. Y., Chen, C. J., Omede, O., Al Qamish, J., Al Naamani, K., Bane, A., Tan, S. S., Simonova, M., Cardenas, I., Derbala, M., Akin, O., Phillips, R. O., Abdelmageed, M. K., Abdulla, M., Adda, D., Al Baqali, A., Al Dweik, N., Al Ejji, K., Al ghazzawi, I., Al Kaabi, S., Al Sadadi, M., Al Salman, J., AlBadri, M., Al‐Busafi, S. A., Al‐Romaihi, H. E., Ampofo, W., Antonov, K., Anyaike, C., Arome, F., Blach, S., Borodo, M. M., Brandon, S. M., Bright, B., Butt, M. T., Chen, D. S., Chen, P. J., Chien, R. N., Chuang, W. L., Cuellar, D., Elbardiny, A. A., Estes, C., Farag, E., Fung, J., Gamkrelidze, I., Garcia, V., Genov, J., Ghandour, Z., Ghuloom, M., Gomez, B., Gunter, J., Habeeb, J., Hajelssedig, O., Hamoudi, W., Himatt, S. M., Hrstic, I., Hu, C. C., Huang, C. F., Hui, Y. T., Jahis, R., Jelev, D., John, A. K., Kaliaskarova, K. S., Kamel, Y., Kao, J. H., Khamis, J., Khattabi, H., Khoudri, I., Konysbekova, A., Kotzev, I., Lai, M. S., Lao, W. C., Layden, J., Lee, M. H., Lesi, O., Li, M., Lo, A., Loo, C. K., Lukšić, B., Maaroufi, A., Malu, A. O., Mateva, L., Mitova, R., Mohamed, R., Morović, M., Murphy, K., Mustapha, B., Nersesov, A., Ngige, E., Njouom, R., Njoya, O., Nonković, D., Obekpa, S., Oguche, S., Okolo, E. E., Omuemu, C., Ondoa, P., Opare‐Sem, O., Owusu‐Ofori, S., Prokopenko, Y. N., Razavi, H., Razavi‐Shearer, D., Razavi‐Shearer, K., Redae, B., Reic, T., Rinke de Wit, T., Rios, C., Robbins, S., Roberts, L. R., Sanad, S. J., Schmelzer, J. D., Sharma, M., Su, T. H., Sultan, K., Tchernev, K., Tsang, O. T. Y., Tsang, S., Tzeuton, C., Ugoeze, S., Uzochukwu, B., Vi, R., Vince, A., Wani, H. U., Wong, V. W. S., Workneh, A., Yacoub, R., Yesmembetov, K. I., Youbi, M., Yuen, M. F., and Nde, H.

Published
2017
Full Text
View/download PDF

19. Historical epidemiology of hepatitis C virus in select countries—volume 4

Author

Maaroufi, A., Vince, A., Himatt, S. M., Mohamed, R., Fung, J., Opare‐Sem, O., Workneh, A., Njouom, R., Al ghazzawi, I., Abdulla, M., Kaliaskarova, K. S., Owusu‐Ofori, S., Abdelmageed, M. K., Adda, D., Akin, O., Al Baqali, A., Al Dweik, N., Al Ejji, K., Al Kaabi, S., Al Naamani, K., Al Qamish, J., Al Sadadi, M., Al Salman, J., AlBadri, M., Al‐Busafi, S. A., Al‐Romaihi, H. E., Ampofo, W., Antonov, K., Anyaike, C., Arome, F., Bane, A., Blach, S., Borodo, M. M., Brandon, S. M., Bright, B., Butt, M. T., Cardenas, I., Chan, H. L. Y., Chen, C. J., Chen, D. S., Chen, P. J., Chien, R. N., Chuang, W. L., Cuellar, D., Derbala, M., Elbardiny, A. A., Estes, C., Farag, E., Gamkrelidze, I., Garcia, V., Genov, J., Ghandour, Z., Ghuloom, M., Gomez, B., Gunter, J., Habeeb, J., Hajelssedig, O., Hamoudi, W., Hrstic, I., Hu, C. C., Huang, C. F., Hui, Y. T., Jahis, R., Jelev, D., John, A. K., Kamel, Y., Kao, J. H., Khamis, J., Khattabi, H., Khoudri, I., Konysbekova, A., Kotzev, I., Lai, M. S., Lao, W. C., Layden, J., Lee, M. H., Lesi, O., Li, M., Lo, A., Loo, C. K., Lukšić, B., Malu, A. O., Mateva, L., Mitova, R., Morović, M., Murphy, K., Mustapha, B., Nde, H., Nersesov, A., Ngige, E., Njoya, O., Nonković, D., Obekpa, S., Oguche, S., Okolo, E. E., Omede, O., Omuemu, C., Ondoa, P., Phillips, R. O., Prokopenko, Y. N., Razavi, H., Razavi‐Shearer, D., Redae, B., Reic, T., Rinke de Wit, T., Rios, C., Robbins, S., Roberts, L. R., Sanad, S. J., Schmelzer, J. D., Sharma, M., Simonova, M., Su, T. H., Sultan, K., Tan, S. S., Tchernev, K., Tsang, O. T. Y., Tsang, S., Tzeuton, C., Ugoeze, S., Uzochukwu, B., Vi, R., Wani, H. U., Wong, V. W. S., Yacoub, R., Yesmembetov, K. I., Youbi, M., Yuen, M. F., and Razavi‐Shearer, K.

Published
2017
Full Text
View/download PDF

23. A time stepping method in analysis of nonlinear structural dynamics

Author

Gholampour A. A., Ghassemieh M., and Razavi H.

Subjects
Direct time integration, Weighted residual, Nonlinear structural dynamics, Higher accuracy, Second order acceleration, Mechanics of engineering. Applied mechanics, TA349-359
Abstract

In this paper a new method is proposed for the direct time integration method for structural dynamics problems. The proposed method assumes second order variations of the acceleration at each time step. Therefore more terms in the Taylor series expansion were used compared to other methods. Because of the increase in order of variations of acceleration, this method has higher accuracy than classical methods. The displacement function is a polynomial with five constants and they are calculated using: two equations for initial conditions (from the end of previous time step), two equations for satisfying the equilibrium at both ends of the time step, and one equation for the weighted residual integration. Proposed method has higher stability and order of accuracy than the other methods.

Published
2011

32. Advancing the global public health agenda for NAFLD: a consensus statement

Author

Lazarus, J.V. Mark, H.E. Anstee, Q.M. Arab, J.P. Batterham, R.L. Castera, L. Cortez-Pinto, H. Crespo, J. Cusi, K. Dirac, M.A. Francque, S. George, J. Hagström, H. Huang, T.T.-K. Ismail, M.H. Kautz, A. Sarin, S.K. Loomba, R. Miller, V. Newsome, P.N. Ninburg, M. Ocama, P. Ratziu, V. Rinella, M. Romero, D. Romero-Gómez, M. Schattenberg, J.M. Tsochatzis, E.A. Valenti, L. Wong, V.W.-S. Yilmaz, Y. Younossi, Z.M. Zelber-Sagi, S. Åberg, F. Adams, L. Khatry, M.S.A. Naamani, K.A. Murillo, O.A. Allen, A.M. Alnaser, F. Alqahtani, S.A. Alswat, K. Alvaro, D. Andrade, R.J. Arrese, M. Awuku, Y.A. Ayesha, M. Baatarkhuu, O. Bakieva, S. Basu, R. Bataller, R. Bedri, S. Bosi, E. Bourliere, M. Bruha, R. Bugianesi, E. Burra, P. Buti, M. Byrne, C.D. Calleja, J.L. Carrieri, P. Carter, F. Fernandez, M.I.C. Castillo-Lopez, G. Castro-Narro, G.E. Chan, H.L.Y. Chan, W.-K. Chang, Y. Colombo, M. Coppell, K.J. Corey, K. Craxi, A. Cryer, D. Dassanayake, A. Martins, A.A.S. de Ledinghen, V. DelPrato, S. Demaio, A. Desalegn, H. Dillon, J. Duseja, A. Dorairaj, P. Ekstedt, M. El Kassas, M. Elsanousi, O.M. Esmat, G. Fan, J.-G. Farpour-Lambert, N. Flisiak, R. Fouad, Y. Fuchs, M. Gani, R.A. Gerber, L. Ghazinyan, H. Gheorghe, L. Goh, G.B.-B. Grønbæk, H. Gulnara, A. Hamid, S. Hebditch, V. Hickman, I.J. Hocking, S.L. Hunyady, B. Idilman, R. Isakov, V.A. Jamal, M.H. Jepsen, P. Iskandar, N.J. Song, M.J. Sudhamshu, K.C. Kakizaki, S. Kalamitsis, G. Kanwal, F. Kao, J.-H. Kaplan, L. Kawaguchi, T. Khader, Y. Kim, S.U. Kodjoh, N. Koek, G. Koike, K. Komas, N.P. Korenjak, M. Kugelmas, M. Labidi, A. Lange, N.F. Lavine, J.E. Lazo, M. Lee, N. Lesmana, C.R.A. Liu, C.-J. Long, M.T. Lopez-Jaramillo, P. Malekzadeh, R. Mahtab, M.A. Marchesini, G. Marinho, R. Vázquez, S.E.M. Mateva, L. Nlombi, C.M. Melin, P. Mikolasevic, I. Milovanovic, T. Musso, C. Nakajima, A. Nava, E. Nersesov, A.V. Nikolova, D. Norris, S. Novak, K. Oben, J. Ong, J.P. Onyekwere, C. Papatheodoridis, G. Paruk, I. Patel, K. Macedo, M.P. Penha-Gonçalves, C. Figueroa, M.P. Hofmann, W.P. Petta, S. de Oliveira, C.P.M.S. Puri, P. Pan, C.Q. Rac, M. Ralston, J. Ramji, A. Razavi, H. Alvares-da-Silva, M.R. Roberts, S. Roden, M. Rose, T. Rouabhia, S. Rovere-Querini, P. Rowe, I.A. Sadirova, S. Salupere, R. Saparbu, T. Sayegh, R. Sebastiani, G. Seki, Y. Selmo, J. Serme, A.K. Shaw, J.E. Shenoy, T. Sheron, N. Shibolet, O. Silva, M. Skrypnyk, I. Socha, P. Soriano, J. Spearman, C.W. Sridharan, K. Suárez, J.J. Sheriff, D.S. Sung, K.-C. Swain, M. Tacke, F. Taheri, S. Tan, S.-S. Tapper, E.B. Yki-Järvinen, H. Thiele, M. Shawa, I.T. Tolmane, I. Torres, E.A. Trauner, M. Treeprasertsuk, S. Turcanu, A. Valantinas, J. Vesterhus, M. Waked, I. Wild, S.H. Willemse, J. Wong, R.J. Xanthakos, S. Young, D.Y. Yu, M.-L. Zheng, K.I. Zeybel, M. Zheng, M.-H. the NAFLD Consensus Consortium

Abstract

Non-alcoholic fatty liver disease (NAFLD) is a potentially serious liver disease that affects approximately one-quarter of the global adult population, causing a substantial burden of ill health with wide-ranging social and economic implications. It is a multisystem disease and is considered the hepatic component of metabolic syndrome. Unlike other highly prevalent conditions, NAFLD has received little attention from the global public health community. Health system and public health responses to NAFLD have been weak and fragmented, and, despite its pervasiveness, NAFLD is largely unknown outside hepatology and gastroenterology. There is only a nascent global public health movement addressing NAFLD, and the disease is absent from nearly all national and international strategies and policies for non-communicable diseases, including obesity. In this global Delphi study, a multidisciplinary group of experts developed consensus statements and recommendations, which a larger group of collaborators reviewed over three rounds until consensus was achieved. The resulting consensus statements and recommendations address a broad range of topics — from epidemiology, awareness, care and treatment to public health policies and leadership — that have general relevance for policy-makers, health-care practitioners, civil society groups, research institutions and affected populations. These recommendations should provide a strong foundation for a comprehensive public health response to NAFLD. © 2021, Springer Nature Limited.

Published
2022

34. Optimization of hepatitis C virus screening strategies by birth cohort in Italy

Author

Kondili L. A., Gamkrelidze I., Blach S., Marcellusi A., Galli M., Petta S., Puoti M., Vella S., Razavi H., Craxi A., Mennini F. S., on behalf of PITER collaborating group, Federico A., Dallio M., Loguercio C., A Kondili, L, Gamkrelidze, I, Blach, S, Marcellusi, A, Galli, M, Petta, S, Puoti, M, Vella, S, Razavi, H, Craxi, A, S Mennini, F, collaborating group, P, Kondili L.A., Gamkrelidze I., Blach S., Marcellusi A., Galli M., Petta S., Puoti M., Vella S., Razavi H., Craxi A., Mennini F.S., Kondili, L. A., Gamkrelidze, I., Blach, S., Marcellusi, A., Galli, M., Petta, S., Puoti, M., Vella, S., Razavi, H., Craxi, A., Mennini, F. S., on behalf of PITER collaborating, Group, Federico, A., Dallio, M., and Loguercio, C.

Subjects
medicine.medical_specialty, Cost effectiveness, Cost-Benefit Analysis, Hepatitis C virus, Settore SECS-P/06, cost-effectivene, Hepacivirus, medicine.disease_cause, Antiviral Agents, World health, NO, 03 medical and health sciences, 0302 clinical medicine, Internal medicine, medicine, Humans, Mass Screening, cost-effectiveness, Antibody screens, Hepatology, Under-five, business.industry, screening, Health services research, health, cost‐effectiveness, Hepatitis C, Chronic, Hepatitis C, Italy, 030220 oncology & carcinogenesis, Settore MED/42, HCV, Original Article, epidemiology, 030211 gastroenterology & hepatology, Liver Disease and Public Health, Quality-Adjusted Life Years, Birth cohort, business, WHO targets, cost-effectiveness, HCV, screening, WHO targets, Demography
Abstract

Background and Aims Cost‐effective screening strategies are needed to make hepatitis C virus (HCV) elimination a reality. We determined if birth cohort screening is cost‐effective in Italy. Methods A model was developed to quantify screening and healthcare costs associated with HCV. The model‐estimated prevalence of undiagnosed HCV was used to calculate the antibody screens needed annually, with a €25 000 cost‐effectiveness threshold. Outcomes were assessed under the status quo and a scenario that met the World Health Organization's targets for elimination of HCV. The elimination scenario was assessed under five screening strategies. Results A graduated birth cohort screening strategy (graduated screening 1: 1968‐1987 birth cohorts, then expanding to 1948‐1967 cohorts) was the least costly. This strategy would gain approximately 144 000 quality‐adjusted life years (QALYs) by 2031 and result in an 89.3% reduction in HCV cases, compared to an 89.6%, 89.0%, 89.7% and 88.7% reduction for inversed graduated screening, 1948‐77 birth cohort, 1958‐77 birth cohort and universal screening, respectively. Graduated screening 1 yielded the lowest incremental cost‐effectiveness ratio (ICER) of €3552 per QALY gained. Conclusions In Italy, a graduated screening scenario is the most cost‐effective strategy. Other countries could consider a similar birth cohort approach when developing HCV screening strategies., See Editorial on Page 1538

Published
2020

35. Novel oxidation of aromatic aldehydes catalyzed by Preyssler's anion, [NaP5W30O110]14

Author

Bamoharram F. F., Roshani M., Alizadeh M. H., Razavi H., and Moghayadi M.

Subjects
Preyssler's anion, catalyst, heteropolyacid, oxidation, benzaldehyde, benzoic acid, Chemistry, QD1-999
Abstract

Preyssler's anion, with formula [NaP5W30O110]14-, catalyzes the oxidation of aromatic aldehydes to related carboxylic acids by hydrogen peroxide as oxidizing agent, under microwave irradiation, or at 70 ºC. Both homogeneous and heterogeneous Preyssler's catalysts (as H14[NaP5W30O110 ]) were used and had their activity compared with those of some Keggin structures. Our data indicate that Sodium30-tungsto pentaphosphate, the so-called Preyssler's anion, with high hydrolytic (pH=0-12) and thermal stability is the best catalyst with high yield and good selectivity. Under microwave irradiation, this polyanion supported on SiO2 was found to be an excellent catalyst for aldehydes with low loss factor in 1-2 min (the loss factor is a measure of the ability of the material to dissipate energy). The effects of various parameters, including catalyst type, nature of the substituent in the aldehyde and temperature, on the yield of the carboxylic acids were studied.

Published
2006

39. Subthreshold Nanosecond Laser in Age-Related Macular Degeneration: Observational Extension Study of the LEAD Clinical Trial

Author

Guymer, Robyn H., primary, Chen, Fred K., additional, Hodgson, Lauren A.B., additional, Caruso, Emily, additional, Harper, Colin A., additional, Wickremashinghe, Sanjeewa S., additional, Cohn, Amy C., additional, Sivarajah, Pyrawy, additional, Tindill, Nicole, additional, Luu, Chi D., additional, Wu, Zhichao, additional, Al-Qureshi, S., additional, Busija, L., additional, Louis, D., additional, Harper, C., additional, Wickremasinghe, S., additional, Van Wijngaarden, P., additional, Lim, L., additional, Durkin, S., additional, Runciman, J., additional, Gihotra, J., additional, Muecke, J., additional, Haywood, K., additional, Brko, C., additional, Paley, J., additional, Smith, M., additional, Luscombe, C., additional, Vincent, R., additional, Lee, D., additional, Guymer, R.H., additional, Luu, C., additional, Wu, Z., additional, Hodgson, L.A.B., additional, Brassington, K., additional, Caruso, E., additional, McGuinness, M., additional, Tindill, N., additional, Aung, K.Z., additional, Baglin, E., additional, Sharangan, P., additional, Harper, C.A., additional, Sandhu, S., additional, Nguyen, T., additional, Cohn, A., additional, Qatarneh, D., additional, Robman, L., additional, Makeyeva, G., additional, Tan, R., additional, Taori, S., additional, Creese, K., additional, Chen, M., additional, Ong, D., additional, No, S., additional, Kandasamy, R., additional, Lim, S.W., additional, Okada, M., additional, Cugley, D., additional, O'Day, R., additional, Keller, P., additional, Lee, K., additional, Alessandrello, E., additional, Alessi-Calandro, J., additional, Kolic, M., additional, Wu, T., additional, Griffin, S., additional, Lek, J.J., additional, Heriot, W., additional, Fagan, X., additional, McIntosh, R., additional, Lowe, C., additional, Boyle, J., additional, Shanahan, O., additional, Chen, F., additional, McAllister, I., additional, Isaacs, T., additional, Shaw, A., additional, Balarantnasingam, C., additional, Chen, Y., additional, Cunningham, W., additional, Viljoen, R., additional, Kennelly, K., additional, Blum, R., additional, Arunachalam, S., additional, Razavi, H., additional, Adams, M., additional, Brown, H., additional, Bryant, J., additional, Cowles, R., additional, Radtke, S., additional, Barry, C., additional, Wong, E., additional, Shilton, F., additional, Soloshenko, A., additional, Jason, A., additional, Lin, A., additional, McSweeney, A., additional, King, A., additional, Shalan, B., additional, Xie, D., additional, Vu, H., additional, Tang, I., additional, Mather, K., additional, Cuypers, M., additional, Cheng, M., additional, McKeone, R., additional, Busby, T., additional, Matthews, R., additional, Lingham, G., additional, Arnold, J., additional, Luckie, A., additional, Chan, D., additional, Chang, J., additional, Tan, T., additional, Koh, L., additional, Cass, H., additional, Fitzsimons, R., additional, Forsyth, T., additional, Nguyen, A., additional, Ghebrial, V., additional, Ayson, H., additional, Graham, A., additional, Firibaldi, M., additional, Chakravarthy, U., additional, Kelly, L., additional, Gillvray, K., additional, Williams, M., additional, Casalino, G., additional, Mangoris, G., additional, Das, R., additional, Peto, T., additional, Toth, L., additional, Quinn, M., additional, Denham, R., additional, Lavery, N.J., additional, Sterrett, G., additional, Silvestri, V., additional, Young, G., additional, Graham, K., additional, Keenan, J., additional, Doyle, L., additional, Douglas, T., additional, Burns, D., additional, Wright, P., additional, and Scullion, L., additional

Published
2021
Full Text
View/download PDF

40. The present and future disease burden of hepatitis C virus infections with todayʼs treatment paradigm – volume 3

Author

Sibley, A., Han, K. H., Abourached, A., Lesmana, L. A., Makara, M., Jafri, W., Salupere, R., Assiri, A. M., Goldis, A., Abaalkhail, F., Abbas, Z., Abdou, A., Al Braiki, F., Al Hosani, F., Al Jaberi, K., Al Khatry, M., Al Mulla, M. A., Al Quraishi, H., Al Rifai, A., Al Serkal, Y., Alam, A., Alavian, S. M., Alashgar, H. I., Alawadhi, S., Al-Dabal, L., Aldins, P., Alfaleh, F. Z., Alghamdi, A. S., Al-Hakeem, R., Aljumah, A. A., Almessabi, A., Alqutub, A. N., Alswat, K. A., Altraif, I., Alzaabi, M., Andrea, N., Babatin, M. A., Baqir, A., Barakat, M. T., Bergmann, O. M., Bizri, A. R., Blach, S., Chaudhry, A., Choi, M. S., Diab, T., Djauzi, S., El Hassan, E. S., El Khoury, S., Estes, C., Fakhry, S., Farooqi, J. I., Fridjonsdottir, H., Gani, R. A., Ghafoor Khan, A., Gheorghe, L., Gottfredsson, M., Gregorcic, S., Gunter, J., Hajarizadeh, B., Hamid, S., Hasan, I., Hashim, A., Horvath, G., Hunyady, B., Husni, R., Jeruma, A., Jonasson, J. G., Karlsdottir, B., Kim, D. Y., Kim, Y. S., Koutoubi, Z., Liakina, V., Lim, Y. S., Löve, A., Maimets, M., Malekzadeh, R., Matičič, M., Memon, M. S., Merat, S., Mokhbat, J. E., Mourad, F. H., Muljono, D. H., Nawaz, A., Nugrahini, N., Olafsson, S., Priohutomo, S., Qureshi, H., Rassam, P., Razavi, H., Razavi-Shearer, D., Razavi-Shearer, K., Rozentale, B., Sadik, M., Saeed, K., Salamat, A., Sanai, F. M., Sanityoso Sulaiman, A., Sayegh, R. A., Sharara, A. I., Siddiq, M., Siddiqui, A. M., Sigmundsdottir, G., Sigurdardottir, B., Speiciene, D., Sulaiman, A., Sultan, M. A., Taha, M., Tanaka, J., Tarifi, H., Tayyab, G., Tolmane, I., Ud din, M., Umar, M., Valantinas, J., Videčnik-Zorman, J., Yaghi, C., Yunihastuti, E., Yusuf, M. A., Zuberi, B. F., and Schmelzer, J. D.

Published
2015
Full Text
View/download PDF

41. Historical epidemiology of hepatitis C virus (HCV) in select countries – volume 3

Author

Liakina, V., Hamid, S., Tanaka, J., Olafsson, S., Sharara, A. I., Alavian, S. M., Gheorghe, L., El Hassan, E. S., Abaalkhail, F., Abbas, Z., Abdou, A., Abourached, A., Al Braiki, F., Al Hosani, F., Al Jaberi, K., Al Khatry, M., Al Mulla, M. A., Al Quraishi, H., Al Rifai, A., Al Serkal, Y., Alam, A., Alashgar, H. I., Alawadhi, S., Al-Dabal, L., Aldins, P., Alfaleh, F. Z., Alghamdi, A. S., Al-Hakeem, R., Aljumah, A. A., Almessabi, A., Alqutub, A. N., Alswat, K. A., Altraif, I., Alzaabi, M., Andrea, N., Assiri, A. M., Babatin, M. A., Baqir, A., Barakat, M. T., Bergmann, O. M., Bizri, A. R., Blach, S., Chaudhry, A., Choi, M. S., Diab, T., Djauzi, S., El Khoury, S., Estes, C., Fakhry, S., Farooqi, J. I., Fridjonsdottir, H., Gani, R. A., Ghafoor Khan, A., Goldis, A., Gottfredsson, M., Gregorcic, S., Hajarizadeh, B., Han, K. H., Hasan, I., Hashim, A., Horvath, G., Hunyady, B., Husni, R., Jafri, W., Jeruma, A., Jonasson, J. G., Karlsdottir, B., Kim, D. Y., Kim, Y. S., Koutoubi, Z., Lesmana, L. A., Lim, Y. S., Löve, A., Maimets, M., Makara, M., Malekzadeh, R., Matičič, M., Memon, M. S., Merat, S., Mokhbat, J. E., Mourad, F. H., Muljono, D. H., Nawaz, A., Nugrahini, N., Priohutomo, S., Qureshi, H., Rassam, P., Razavi, H., Razavi-Shearer, D., Razavi-Shearer, K., Rozentale, B., Sadik, M., Saeed, K., Salamat, A., Salupere, R., Sanai, F. M., Sanityoso Sulaiman, A., Sayegh, R. A., Schmelzer, J. D., Sibley, A., Siddiq, M., Siddiqui, A. M., Sigmundsdottir, G., Sigurdardottir, B., Speiciene, D., Sulaiman, A., Sultan, M. A., Taha, M., Tarifi, H., Tayyab, G., Tolmane, I., Ud din, M., Umar, M., Valantinas, J., Videčnik-Zorman, J., Yaghi, C., Yunihastuti, E., Yusuf, M. A., Zuberi, B. F., and Gunter, J.

Published
2015
Full Text
View/download PDF

42. Strategies to manage hepatitis C virus infection disease burden – volume 3

Author

Alfaleh, F. Z., Nugrahini, N., Matičič, M., Tolmane, I., Alzaabi, M., Hajarizadeh, B., Valantinas, J., Kim, D. Y., Hunyady, B., Abaalkhail, F., Abbas, Z., Abdou, A., Abourached, A., Al Braiki, F., Al Hosani, F., Al Jaberi, K., Al Khatry, M., Al Mulla, M. A., Al Quraishi, H., Al Rifai, A., Al Serkal, Y., Alam, A., Alashgar, H. I., Alavian, S. M., Alawadhi, S., Al-Dabal, L., Aldins, P., Alghamdi, A. S., Al-Hakeem, R., Aljumah, A. A., Almessabi, A., Alqutub, A. N., Alswat, K. A., Altraif, I., Andrea, N., Assiri, A. M., Babatin, M. A., Baqir, A., Barakat, M. T., Bergmann, O. M., Bizri, A. R., Chaudhry, A., Choi, M. S., Diab, T., Djauzi, S., El Hassan, E. S., El Khoury, S., Estes, C., Fakhry, S., Farooqi, J. I., Fridjonsdottir, H., Gani, R. A., Ghafoor Khan, A., Gheorghe, L., Goldis, A., Gottfredsson, M., Gregorcic, S., Gunter, J., Hamid, S., Han, K. H., Hasan, I., Hashim, A., Horvath, G., Husni, R., Jafri, W., Jeruma, A., Jonasson, J. G., Karlsdottir, B., Kim, Y. S., Koutoubi, Z., Lesmana, L. A., Liakina, V., Lim, Y. S., Löve, A., Maimets, M., Makara, M., Malekzadeh, R., Memon, M. S., Merat, S., Mokhbat, J. E., Mourad, F. H., Muljono, D. H., Nawaz, A., Olafsson, S., Priohutomo, S., Qureshi, H., Rassam, P., Razavi, H., Razavi-Shearer, D., Razavi-Shearer, K., Rozentale, B., Sadik, M., Saeed, K., Salamat, A., Salupere, R., Sanai, F. M., Sanityoso Sulaiman, A., Sayegh, R. A., Schmelzer, J. D., Sharara, A. I., Sibley, A., Siddiq, M., Siddiqui, A. M., Sigmundsdottir, G., Sigurdardottir, B., Speiciene, D., Sulaiman, A., Sultan, M. A., Taha, M., Tanaka, J., Tarifi, H., Tayyab, G., Ud din, M., Umar, M., Videčnik-Zorman, J., Yaghi, C., Yunihastuti, E., Yusuf, M. A., Zuberi, B. F., and Blach, S.

Published
2015
Full Text
View/download PDF

45. Community Eye Health MSc dissertations

Author

Osman L, Cockburn N, Fawad M, Razavi H, Abdull M, Mutombo TK, and Leite C

Subjects
Delivery of Health Care, Refugees, Keratitis, Child, blindness, Corneal Diseases, Vitamin A Deficiency, Research, methods, Low Vision, Incidence, Traditional Medicine, Cost, Cataract, Health Behaviour, Ophthalmology, RE1-994
Abstract

The seven Exchange articles that follow are based on the dissertations of students at the International Centre for Eye Health, London School of Hygiene and Tropical Medicine, who graduated in 2008.

Published
2008

47. The present and future disease burden of hepatitis C virus (HCV) infections with todayʼs treatment paradigm – volume 2

Author

Hatzakis, A., Chulanov, V., Gadano, A. C., Bergin, C., Ben-Ari, Z., Mossong, J., Schréter, I., Baatarkhuu, O., Acharya, S., Aho, I., Anand, A. C., Andersson, M. I., Arendt, V., Arkkila, P., Barclay, K., Bessone, F., Blach, S., Blokhina, N., Brunton, C. R., Choudhuri, G., Cisneros, L., Croes, E. A., Dahgwahdorj, Y. A., Dalgard, O., Daruich, J. R., Dashdorj, N. R., Davaadorj, D., de Knegt, R. J., de Vree, M., Estes, C., Flisiak, R., Gane, E., Gower, E., Halota, W., Henderson, C., Hoffmann, P., Hornell, J., Houlihan, D., Hrusovsky, S., Jarčuška, P., Kershenobich, D., Kostrzewska, K., Kristian, P., Leshno, M., Lurie, Y., Mahomed, A., Mamonova, N., Mendez-Sanchez, N., Norris, S., Nurmukhametova, E., Nymadawa, P., Oltman, M., Oyunbileg, J., Oyunsuren, Ts., Papatheodoridis, G., Pimenov, N., Prabdial-Sing, N., Prins, M., Radke, S., Rakhmanova, A., Razavi-Shearer, K., Reesink, H. W., Ridruejo, E., Safadi, R., Sagalova, O., Avila, Sanchez J. F., Sanduijav, R., Saraswat, V., Seguin-Devaux, C., Shah, S. R., Shestakova, I., Shevaldin, A., Shibolet, O., Silva, M. O., Sokolov, S., Sonderup, M., Souliotis, K., Spearman, C. W., Staub, T., Stedman, C., Strebkova, E. A., Struck, D., Sypsa, V., Tomasiewicz, K., Undram, L., van der Meer, A. J., van Santen, D., Veldhuijzen, I., Villamil, F. G., Willemse, S., Zuckerman, E., Zuure, F. R., Puri, P., and Razavi, H.

Published
2015
Full Text
View/download PDF

48. Strategies to manage hepatitis C virus (HCV) infection disease burden – volume 2

Author

Gane, E., Kershenobich, D., Seguin-Devaux, C., Kristian, P., Aho, I., Dalgard, O., Shestakova, I., Nymadawa, P., Blach, S., Acharya, S., Anand, A. C., Andersson, M. I., Arendt, V., Arkkila, P., Baatarkhuu, O., Barclay, K., Ben-Ari, Z., Bergin, C., Bessone, F., Blokhina, N., Brunton, C. R., Choudhuri, G., Chulanov, V., Cisneros, L., Croes, E. A., Dahgwahdorj, Y. A., Daruich, J. R., Dashdorj, N. R., Davaadorj, D., de Knegt, R. J., de Vree, M., Gadano, A. C., Gower, E., Halota, W., Hatzakis, A., Henderson, C., Hoffmann, P., Hornell, J., Houlihan, D., Hrusovsky, S., Jarčuška, P., Kostrzewska, K., Leshno, M., Lurie, Y., Mahomed, A., Mamonova, N., Mendez-Sanchez, N., Mossong, J., Norris, S., Nurmukhametova, E., Oltman, M., Oyunbileg, J., Oyunsuren, Ts., Papatheodoridis, G., Pimenov, N., Prins, M., Puri, P., Radke, S., Rakhmanova, A., Razavi, H., Razavi-Shearer, K., Reesink, H. W., Ridruejo, E., Safadi, R., Sagalova, O., Avila, Sanchez J. F., Sanduijav, R., Saraswat, V., Schréter, I., Shah, S. R., Shevaldin, A., Shibolet, O., Silva, M. O., Sokolov, S., Sonderup, M., Souliotis, K., Spearman, C. W., Staub, T., Stedman, C., Strebkova, E. A., Struck, D., Sypsa, V., Tomasiewicz, K., Undram, L., van der Meer, A. J., van Santen, D., Veldhuijzen, I., Villamil, F. G., Willemse, S., Zuckerman, E., Zuure, F. R., Prabdial-Sing, N., Flisiak, R., and Estes, C.

Published
2015
Full Text
View/download PDF

49. Historical epidemiology of hepatitis C virus (HCV) in select countries – volume 2

Author

Saraswat, V., Norris, S., de Knegt, R. J., Avila, Sanchez J. F., Sonderup, M., Zuckerman, E., Arkkila, P., Stedman, C., Acharya, S., Aho, I., Anand, A. C., Andersson, M. I., Arendt, V., Baatarkhuu, O., Barclay, K., Ben-Ari, Z., Bergin, C., Bessone, F., Blach, S., Blokhina, N., Brunton, C. R., Choudhuri, G., Chulanov, V., Cisneros, L., Croes, E. A., Dahgwahdorj, Y. A., Dalgard, O., Daruich, J. R., Dashdorj, N. R., Davaadorj, D., de Vree, M., Estes, C., Flisiak, R., Gadano, A. C., Gane, E., Halota, W., Hatzakis, A., Henderson, C., Hoffmann, P., Hornell, J., Houlihan, D., Hrusovsky, S., Jarčuška, P., Kershenobich, D., Kostrzewska, K., Kristian, P., Leshno, M., Lurie, Y., Mahomed, A., Mamonova, N., Mendez-Sanchez, N., Mossong, J., Nurmukhametova, E., Nymadawa, P., Oltman, M., Oyunbileg, J., Oyunsuren, Ts., Papatheodoridis, G., Pimenov, N., Prabdial-Sing, N., Prins, M., Puri, P., Radke, S., Rakhmanova, A., Razavi, H., Razavi-Shearer, K., Reesink, H. W., Ridruejo, E., Safadi, R., Sagalova, O., Sanduijav, R., Schréter, I., Seguin-Devaux, C., Shah, S. R., Shestakova, I., Shevaldin, A., Shibolet, O., Sokolov, S., Souliotis, K., Spearman, C. W., Staub, T., Strebkova, E. A., Struck, D., Tomasiewicz, K., Undram, L., van der Meer, A. J., van Santen, D., Veldhuijzen, I., Villamil, F. G., Willemse, S., Zuure, F. R., Silva, M. O., Sypsa, V., and Gower, E.

Published
2015
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results